Population Pharmacokinetics of Rifabutin in Human Immunodeficiency Virus-Infected Patients

Rifabutin pharmacokinetics were studied by the population approach (NONMEM) with 40 human immunodeficiency virus-infected patients receiving rifabutin at different doses for prophylaxis or therapy of mycobacterial infections. A two-compartment open model with first-order absorption was used as the s...

Descrición completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Principais autores:	Gatti, Giorgio, Papa, Pietro, Torre, Donato, Andreoni, Massimo, Poggio, Antonio, Bassetti, Matteo, Marone, Piero
Formato:	Artigo
Idioma:	Inglês
Publicado:	American Society for Microbiology (ASM) 1998
Assuntos:	Pharmacology
Acceso en liña:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105726/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9687400/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.8.2017
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!